Herantis Pharma Oyj
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HRTIS.HE research report →
About the company
Herantis Pharma Oyj, a biotechnology company founded in Espoo, Finland, in 2008, is dedicated to developing innovative, disease-modifying CDNF-based treatments for Parkinson's disease (PD). Its pipeline features two key assets: HER-096, an advanced small, synthetic chemical peptidomimetic (a modified version of the active CDNF parent molecule) which is in preclinical stages as an xCDNF candidate for Parkinson's and other neurodegenerative conditions; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein currently in Phase I clinical trials for patients with PD.
- CEO
- Antti Vuolanto
- IPO
- 2014
- Employees
- 11
- HQ
- Espoo, FI
Price Chart
- Market Cap
- $49.56M
- P/E
- -6.93
- P/S
- 0.00
- P/B
- -26.71
- EV/EBITDA
- -8.17
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -21354.84%
- ROIC
- -363.20%
- Revenue
- $0 · 0.00%
- Net Income
- $-6,620,000 · -34.04%
- EPS
- $-0.28 · -16.67%
- Op Income
- $-6,395,000
- FCF YoY
- 6.87%
- 52W High
- $3.87
- 52W Low
- $1.28
- 50D MA
- $1.83
- 200D MA
- $2.02
- Beta
- 0.63
- Avg Volume
- 29.73K
Get TickerSpark's AI analysis on HRTIS.HE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HRTIS.HE coverage
Recent articles, reports, and earnings notes.
No research on HRTIS.HE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HRTIS.HE report →Similar companies
Peers in the same neighborhood.